An inhibitor of Janus kinase 2 prevents polycythemia in mice

Biochemical Pharmacology

Volumn 78, Issue 4, 2009, Pages 382-389

  Mathur, Anjili ^a   Mo, Jan Rung ^a   Kraus, Manfred ^a   O'Hare, Erin ^a   Sinclair, Peter ^a   Young, Jonathan ^a   Zhao, Shuxia ^a   Wang, Yuxun ^a   Kopinja, Johnny ^a   Qu, Xianlu ^a   Reilly, John ^a   Walker, Deborah ^a   Xu, Lin ^a   Aleksandrowicz, Daniel ^a   Marshall, Gary ^a   Scott, Martin L ^a   Kohl, Nancy E ^a   Bachman, Eric ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Epo; Erythropoietin; Jak2; Polycythemia vera; Stat5

Indexed keywords

JANUS KINASE 2; JANUS KINASE INHIBITOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PYRIDONE 1; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE MODEL; DRUG MECHANISM; DRUG RESPONSE; DRUG STRUCTURE; ENZYME INHIBITION; ERYTHROID PRECURSOR CELL; HEMATOCRIT; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SPLEEN SIZE; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELL PROLIFERATION; ENZYME INHIBITORS; ERYTHROID PRECURSOR CELLS; HUMANS; JANUS KINASE 2; MICE; PHOSPHORYLATION; POLYCYTHEMIA; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; PROTEIN-TYROSINE KINASES; PYRIDONES; SIGNAL TRANSDUCTION; THROMBOCYTHEMIA, ESSENTIAL; TUMOR CELLS, CULTURED;

EID: 67349271581     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.04.025     Document Type: Article

References (52)

1. Tefferi A., and Spivak J.L. Polycythemia vera: scientific advances and current practice. Semin Hematol 42 4 (2005) 206-220
2. Zhao R., Xing S., Li Z., Fu X., Li Q., Krantz S.B., et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 280 24 (2005) 22788-22792
3. James C., Ugo V., Le Couédic J.P., Staerk J., Delhommeau F., Lacout C., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434 7037 (2005) 1144-1148
4. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352 17 (2005) 1779-1790
5. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7 4 (2005) 387-397
6. Chievitz E., and Thiede T. Complications and causes of death in polycythaemia vera. Acta Med Scand 172 (1962) 513-523
7. Landolfi R., Marchioli R., Kutti J., Gisslinger H., Tognoni G., Patrono C., et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 350 2 (2004) 114-124
8. Passamonti F., Rumi E., Pungolino E., Malabarba L., Bertazzoni P., Valentini M., et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 117 10 (2004) 755-761
9. Merup M., Aberg W., Löfvenberg E., Svensson E., Engman K., Paul C., et al. Symptoms, symptom distress and health-related quality of life in patients with polycythaemia vera or essential thrombocythaemia during treatment with interferon-alpha. Acta Oncol 41 1 (2002) 50-55
10. Diehn F., and Tefferi A. Pruritus in polycythaemia vera: prevalence, laboratory correlates and management. Br J Haematol 115 3 (2001) 619-621
11. Vannucchi A.M., Antonioli E., Guglielmelli P., Rambaldi A., Barosi G., Marchioli R., et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 110 3 (2007) 840-846 [Epub 2007, Mar 22]
12. Mesa R.A., Niblack J., Wadleigh M., Verstovsek S., Camoriano J., Barnes S., et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer 109 1 (2007) 68-76
13. Schafer A.I. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood 107 11 (2006) 4214-4222
14. Tefferi A. Polycythemia vera: a comprehensive review and clinical recommendations. Mayo Clin Proc 78 2 (2003) 174-194
15. Kisseleva T., Bhattacharya S., Braunstein J., and Schindler C.W. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 285 1-2 (2002) 1-24
16. Lodish H.F., Hilton D.J., Klingmüller U., Watowich S.S., and Wu H. The erythropoietin receptor: biogenesis, dimerization, and intracellular signal transduction. Cold Spring Harb Symp Quant Biol 60 (1995) 93-104
17. Socolovsky M., Nam H., Fleming M.D., Haase V.H., Brugnara C., and Lodish H.F. Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts. Blood 98 12 (2001) 3261-3273
18. Constantinescu S.N., Ghaffari S., and Lodish H.F. The erythropoietin receptor: structure, activation and intracellular signal transduction. Trends Endocrinol Metab 10 1 (1999) 18-23
19. Socolovsky M., Fallon A.E., Wang S., Brugnara C., and Lodish H.F. Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction. Cell 98 2 (1999) 181-191
20. Parganas E., Wang D., Stravopodis D., Topham D.J., Marine J.C., Teglund S., et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93 3 (1998) 385-395
21. Wu H., Liu X., Jaenisch R., and Lodish H.F. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 83 1 (1995) 59-67
22. Wernig G., Mercher T., Okabe R., Levine R.L., Lee B.H., and Gilliland D.G. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107 11 (2006) 4274-4281
23. Zaleskas V.M., Krause D.S., Lazarides K., Patel N., Hu Y., Li S., et al. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS ONE 1 (2006) pe18
24. Lacout C., Pisani D.F., Tulliez M., Gachelin F.M., Vainchenker W., and Villeval J.L. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 108 5 (2006) 1652-1660
25. Bumm T.G., Elsea C., Corbin A.S., Loriaux M., Sherbenou D., Wood L., et al. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res 66 23 (2006) 11156-11165
26. Lu X., Levine R., Tong W., Wernig G., Pikman Y., Zarnegar S., et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci U S A 102 52 (2005) 18962-18967
27. Thompson J.E. JAK protein kinase inhibitors. Drug News Perspect 18 5 (2005) 305-310
28. Thompson J.E., Cubbon R.M., Cummings R.T., Wicker L.S., Frankshun R., Cunningham B.R., et al. Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg Med Chem Lett 12 8 (2002) 1219-1223
29. Quentmeier H., MacLeod R.A., Zaborski M., and Drexler H.G. JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia 20 3 (2006) 471-476
30. Walz C., Crowley B.J., Hudon H.E., Gramlich J.L., Neuberg D.S., Podar K., et al. Activated Jak2 with the V617F point mutation promotes G1/S phase transition. J Biol Chem 281 26 (2006) 18177-18183
31. McDonald T.P., Clift R.E., and Cottrell M.B. Large, chronic doses of erythropoietin cause thrombocytopenia in mice. Blood 80 2 (1992) 352-358
32. Lee D.E., Son W., Ha B.J., Oh M.S., and Yoo O.J. The prolonged half-lives of new erythropoietin derivatives via peptide addition. Biochem Biophys Res Commun 339 1 (2006) 380-385
33. Silva M., Richard C., Benito A., Sanz C., Olalla I., and Fernández-Luna J.L. Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N Engl J Med 338 9 (1998) 564-571
34. Sathyanarayana P., Menon M.P., Bogacheva O., Bogachev O., Niss K., Kapelle W.S., et al. Erythropoietin modulation of podocalyxin and a proposed erythroblast niche. Blood 110 2 (2007) 509-518
35. Ghaffari S., Kitidis C., Zhao W., Marinkovic D., Fleming M.D., Luo B., et al. AKT induces erythroid-cell maturation of JAK2-deficient fetal liver progenitor cells and is required for Epo regulation of erythroid-cell differentiation. Blood 107 5 (2006) 1888-1891
36. Ghaffari S., Kitidis C., Fleming M.D., Neubauer H., Pfeffer K., and Lodish H.F. Erythropoiesis in the absence of janus-kinase 2: BCR-ABL induces red cell formation in JAK2(-/-) hematopoietic progenitors. Blood 98 10 (2001) 2948-2957
37. Schindler C., Levy D.E., and Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem 282 28 (2007) 20059-20063
38. Garçon L., Rivat C., James C., Lacout C., Camara-Clayette V., Ugo V., et al. Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells. Blood 108 5 (2006) 1551-1554
39. Pardanani A., Hood J., Lasho T., Levine R.L., Martin M.B., Noronha G., et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 21 8 (2007) 1658-1668
40. Arcasoy M.O., and Jiang X. Co-operative signalling mechanisms required for erythroid precursor expansion in response to erythropoietin and stem cell factor. Br J Haematol 130 1 (2005) 121-129
41. Rodig S.J., Meraz M.A., White J.M., Lampe P.A., Riley J.K., Arthur C.D., et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 93 3 (1998) 373-383
42. Karaghiosoff M., Neubauer H., Lassnig C., Kovarik P., Schindler H., Pircher H., et al. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 13 4 (2000) 549-560
43. Shimoda K., Kato K., Aoki K., Matsuda T., Miyamoto A., Shibamori M., et al. Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. Immunity 13 4 (2000) 561-571
44. Nosaka T., van Deursen J.M., Tripp R.A., Thierfelder W.E., Witthuhn B.A., McMickle A.P., et al. Defective lymphoid development in mice lacking Jak3. Science 270 5237 (1995) 800-802
45. Park S.Y., Saijo K., Takahashi T., Osawa M., Arase H., Hirayama N., et al. Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity 3 6 (1995) 771-782
46. Paniagua R., Si M.S., Flores M.G., Rousvoal G., Zhang S., Aalami O., et al. Effects of JAK3 inhibition with CP-690,550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts. Transplantation 80 9 (2005) 1283-1292
47. Pearson T.C. Evaluation of diagnostic criteria in polycythemia vera. Semin Hematol 38 1 Suppl. 2 (2001) 21-24
48. Levine R.L., Loriaux M., Huntly B.J., Loh M.L., Beran M., Stoffregen E., et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 106 10 (2005) 3377-3379
49. Scott L.M., Tong W., Levine R.L., Scott M.A., Beer P.A., Stratton M.R., et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356 5 (2007) 459-468
50. Tefferi A., and Gilliland D.G. Oncogenes in myeloproliferative disorders. Cell Cycle 6 5 (2007) 550-566
51. Hookham M.B., Elliott J., Suessmuth Y., Staerk J., Ward A.C., Vainchenker W., et al. The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood 109 11 (2007) 4924-4929
52. Kennedy J.A., Barabé F., Patterson B.J., Bayani J., Squire J.A., Barber D.L., et al. Expression of TEL-JAK2 in primary human hematopoietic cells drives erythropoietin-independent erythropoiesis and induces myelofibrosis in vivo. Proc Natl Acad Sci U S A 103 45 (2006) 16930-16935